Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

New discount persuades NICE to bless J&J's Zytiga

Britain's cost-effectiveness watchdog reversed its decision against the Johnson & Johnson prostate cancer pill, thanks to the company's new discount offer.

Big Pharma's high-risk pursuit of CNS gold faces major market doubts

Here's an interesting number for anyone interested in the risks and rewards of drug development: Two of every three analysts and fund managers recently queried by the ISI Group say they expect that new Alzheimer's drugs in late-stage testing at Eli Lilly and Pfizer/J&J will fail.

J&J opens up Doxil rationing on 'limited' new supply

After months of restricting Doxil treatment to current patients, Johnson & Johnson has opened up its rationing program to new ones.

J&J buys first Chinese medical device company

Johnson & Johnson ($JNJ) made a big move in China this week with the purchase of its first medical device company in that country. It picked up Guangzhou Bioseal Biotech for an undisclosed sum.

Many U.S. companies not top drugsellers in U.S.

The report says spending on branded drugs in the U.S. increased 2.2% in actual dollars to $258 billion from $252 billion, based on data from IMS Health.

St. Jude, Edwards among those named as potential J&J M&A targets

Analysts think St. Jude Medical ($STJ) and Edwards Lifesciences ($EW) could be eyed by Johnson & Johnson ($JNJ) as potential pickups.

Gorsky starts the marathon task of rehabbing J&J

Johnson & Johnson's Alex Gorsky hung up his hat in the CEO office today. He'll also have to roll up his sleeves.

Fixing OTC production problems is a top priority for new J&J CEO

Resolving manufacturing problems so Johnson & Johnson can get its once well-regarded consumer brands back in consumers hands is Alex Gorsky's first priority as he officially takes the reins as CEO today.

J&J's Gorsky will target device deals for emerging markets

Expect Johnson & Johnson ($JNJ) to start spending some of its $14 billion in cash on medical device deals to help expand its presence in emerging markets once Alex Gorsky becomes CEO.

Novartis remediation drags on longer than expected

In reporting an 8% first-quarter earnings decline to shareholders, Novartis acknowledged the company's inability to meet GMPs at a variety of plants played a big role in that dip.